Guizhou Yibai Pharmaceutical Co., Ltd.

SHSE:600594 Stock Report

Market Cap: CN¥3.0b

Guizhou Yibai Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Guizhou Yibai Pharmaceutical's earnings have been declining at an average annual rate of -21.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 6.6% per year.

Key information

-21.9%

Earnings growth rate

-21.9%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-6.6%
Return on equity-8.8%
Net Margin-9.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Guizhou Yibai Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:600594 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,398-2361,481117
30 Jun 242,509-1311,517116
31 Mar 242,709-91,589112
31 Dec 232,8211031,587112
30 Sep 232,773-4531,509122
30 Jun 232,769-4251,516123
31 Mar 232,731-4331,497129
31 Dec 222,735-4261,533127
30 Sep 222,8401431,628125
30 Jun 223,1062001,801125
31 Mar 223,2102231,871128
31 Dec 213,3472441,986136
30 Sep 213,5863352,075153
30 Jun 213,6272792,153149
31 Mar 213,5512402,110165
31 Dec 203,4132292,043146
30 Sep 203,2861762,04389
30 Jun 203,2251612,073106
31 Mar 203,2241432,092108
31 Dec 193,3611422,164119
30 Sep 193,480-7652,291132
30 Jun 193,599-7892,265122
31 Mar 193,744-7682,33485
31 Dec 183,883-7252,36377
30 Sep 183,8452682,29299
30 Jun 183,7483702,154100
31 Mar 183,8413882,22883
31 Dec 173,8083882,19771
30 Sep 173,8774112,17730
30 Jun 173,9133962,2650
31 Mar 173,8814032,2520
31 Dec 163,6873852,2050
30 Sep 163,5193172,2650
30 Jun 163,4393022,2780
31 Mar 163,3642142,3590
31 Dec 153,3031892,3330
30 Sep 153,5323322,3790
30 Jun 153,4963722,3200
31 Mar 153,2234822,0080
31 Dec 143,1574781,9800
30 Sep 143,1204831,9410
30 Jun 143,0014631,8440
31 Mar 142,8864411,7810
31 Dec 132,7854291,7090

Quality Earnings: 600594 is currently unprofitable.

Growing Profit Margin: 600594 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 600594 is unprofitable, and losses have increased over the past 5 years at a rate of 21.9% per year.

Accelerating Growth: Unable to compare 600594's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 600594 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).

Return on Equity

High ROE: 600594 has a negative Return on Equity (-8.8%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 12:44
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guizhou Yibai Pharmaceutical Co., Ltd. is covered by 20 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Chi Man WongChina Galaxy International Securities (Hong Kong)
Haigang ChenChina International Capital Corporation Limited